![]() |
![]() |
In association with
|
|
Forward to a colleague |
||
Access Full Stories UK-base William Ransom & Son has been advised to voluntarily recall certain products following a false contamination scare at its Witham, Essex, facility... Read Millipore partners Rohm and Haas to develop new chromatography media Separations expert Millipore is collaborating with Rohm and Haas Company to develop new high-performance chromatography products for use in biopharmaceutical manufacturing... Read Pharmaceutical manufacturing: news in brief In-PharmaTechnologist.com brings you a selection of recent headlines from around the pharmaceutical manufacturing industry... Read BMS reveals plans to trim the fat Bristol-Myers Squibb (BMS) has finally detailed its plans to trim the fat and save cash, months after first revealing that big changes would be on the cards... Read Abbott cuts jobs, closes plant in Ireland Abbott is to shut its doors on its Galway, Ireland, facility - taking 500 jobs with it - as the market moves into murky waters over the future of vascular stents... Read |
||||||||||||||||||
All News Headlines for: December | November | October |
||||||||||||||||||
Transdermal Sufentanil Licensing Opportunity Aveva's 7-day sufentanil's advanced technology and patient benefits will enable Aveva and its Partner to capture a significant share of the existing $3.9 billion dollar chronic pain market... Click Here | ||||||||||||||||||
|
Related Industry News Microfluidics promises a bright future for cell-based assays UK researchers have published results that show that microfluidic devices can provide robust quantitative pharmacological information from low numbers of single cells... Read Genetic 'ID cards' enable meat traceability A new genetic identity test that can be used to confirm the breed and origin of meat from farm animals has been developed to enable complete meat traceability... Read Eisai selects Singapore as Asia trials hub Eisai is planning to step up its clinical research presence in Asia and has chosen Singapore as a hub from which to coordinate its research activities... Read Morphosys to exit fee-for-service upon Novartis deal Morphosys has landed in the money after scoring a lucrative 10 year antibody development deal with Novartis and as a result, will now place all its eggs in one basket and cut ties with its fee-for-service customers... Read
|
||||||||||||||||||
|
|||||
Forward to a colleague |
|||||
To continue to receive this newsletter in your inbox, please add newsletter@In-PharmaTechnologist.com to your address book |
||
Update preferences | Change your email address | Unsubscribe |
||
Contact us: Advertising | Recruitment | Privacy policy | Terms & conditions | Feedback |
||
| © 2007 - Decision News Media S.A.S - All Rights Reserved Le Belem - 355, rue Vendemiaire - 34000 Montpellier - France http://www.decisionnewsmedia.com |
||